Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Stevanato Group SpA (STVN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: STVN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
11 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Year Target Price $27.33
Year Target Price $27.33
| 6 | Strong Buy |
| 2 | Buy |
| 3 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit -7.43% | Avg. Invested days 36 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 6.72B USD | Price to earnings Ratio 45.63 | 1Y Target Price 28.61 |
Price to earnings Ratio 45.63 | 1Y Target Price 28.61 | ||
Volume (30-day avg) - | Beta 0.53 | 52 Weeks Range 17.07 - 25.88 | Updated Date 06/29/2025 |
52 Weeks Range 17.07 - 25.88 | Updated Date 06/29/2025 | ||
Dividends yield (FY) 0.25% | Basic EPS (TTM) 0.54 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 11.16% | Operating Margin (TTM) 13.97% |
Management Effectiveness
Return on Assets (TTM) 4.88% | Return on Equity (TTM) 9.14% |
Valuation
Trailing PE 45.63 | Forward PE 40.16 | Enterprise Value 7078041112 | Price to Sales(TTM) 5.98 |
Enterprise Value 7078041112 | Price to Sales(TTM) 5.98 | ||
Enterprise Value to Revenue 5.38 | Enterprise Value to EBITDA 23.64 | Shares Outstanding 49604600 | Shares Floating 48805190 |
Shares Outstanding 49604600 | Shares Floating 48805190 | ||
Percent Insiders 1.68 | Percent Institutions 112.69 |
Analyst Ratings
Rating 4.27 | Target Price 27.33 | Buy 2 | Strong Buy 6 |
Buy 2 | Strong Buy 6 | ||
Hold 3 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Stevanato Group SpA
Company Overview
History and Background
Stevanato Group SpA was founded in 1949 in Italy. It has grown from a glass tubing manufacturer to a global provider of drug containment, drug delivery, and diagnostic solutions for the pharmaceutical, biotechnology, and life sciences industries. The company has expanded through organic growth and acquisitions, establishing a significant presence worldwide.
Core Business Areas
- Biopharmaceutical and Diagnostic Solutions: Offers a range of products and services to the biopharmaceutical and diagnostic industries, including vials, cartridges, syringes, and containers for diagnostics. Also includes engineering services.
- Drug Delivery Systems: Focuses on designing, developing, and manufacturing drug delivery systems, including pen injectors and autoinjectors, which are designed to enhance patient adherence and improve drug efficacy.
- Engineering: Provides visual inspection systems for the pharmaceutical market, inspection and control systems and automation solutions.
Leadership and Structure
The company is led by Franco Stevanato (Chairman) and Franco Moro (Chief Executive Officer). The organizational structure includes various functional departments, such as operations, research and development, sales and marketing, and finance.
Top Products and Market Share
Key Offerings
- Glass Vials: A major product. Used for storing injectable drugs. Stevanato is the 2nd largest vial manufacturer globally and is gaining market share. Competitors include Corning, SCHOTT, Gerresheimer, and SGD Pharma.
- Prefillable Syringes: Syringes that are pre-filled by the manufacturer for easier and safer administration of injectable drugs. Stevanato is the 2nd largest supplier worldwide. Competitors include Becton Dickinson (BD), Gerresheimer and SCHOTT.
- Cartridges for Insulin Pens: Cartridges used in insulin pens for diabetes management. Competitors include BD, Ypsomed, and Owen Mumford.
- Visual Inspection Systems: Automatic and semi-automatic inspection machines, to meet any market requirement in terms of capacity, inspection performance and investment level. Competitors include Antares Vision Group, Omron.
Market Dynamics
Industry Overview
The pharmaceutical packaging and drug delivery market is growing due to factors such as the increasing demand for injectable drugs, the rise in chronic diseases, and technological advancements in drug delivery systems.
Positioning
Stevanato Group SpA holds a strong position in the market, particularly in glass vials and prefillable syringes. Its competitive advantages include its extensive product portfolio, global manufacturing footprint, and long-standing relationships with pharmaceutical companies.
Total Addressable Market (TAM)
The total addressable market for pharmaceutical packaging and drug delivery systems is estimated to be in the billions of dollars annually. Stevanato Group SpA is well-positioned to capture a significant portion of this market.
Upturn SWOT Analysis
Strengths
- Global manufacturing footprint
- Extensive product portfolio
- Strong relationships with pharmaceutical companies
- Innovation in drug delivery systems
Weaknesses
- Dependence on pharmaceutical industry trends
- Exposure to raw material price fluctuations
- Potential supply chain disruptions
Opportunities
- Expansion into emerging markets
- Increased demand for biologics and biosimilars
- Development of new drug delivery technologies
- Growth in injectable drug market
Threats
- Intense competition
- Stringent regulatory requirements
- Patent infringement risks
- Economic downturns
Competitors and Market Share
Key Competitors
- BDX
- GXI.DE
- WRK.DE
Competitive Landscape
Stevanato Group SpA competes with other major players in the pharmaceutical packaging and drug delivery market. It differentiates itself through its comprehensive product portfolio, global reach, and commitment to innovation. Compared to some of its competitors, the company has a sharper focus on pharma, making it faster to respond and pivot.
Major Acquisitions
Balda AG
- Year: 2016
- Acquisition Price (USD millions): 110
- Strategic Rationale: Expanded capabilities in plastic components for drug delivery systems.
Growth Trajectory and Initiatives
Historical Growth: Stevanato Group SpA has demonstrated steady growth in revenue and profitability over the past few years, driven by increased demand for its products and services.
Future Projections: Analysts project continued growth for Stevanato Group SpA, driven by its expansion in emerging markets, its focus on innovative drug delivery solutions, and the growth of the pharmaceutical industry.
Recent Initiatives: Recent initiatives include expanding manufacturing capacity, investing in R&D, and pursuing strategic acquisitions to strengthen its market position.
Summary
Stevanato Group SpA is a strong player in the pharmaceutical packaging and drug delivery market, with a solid growth trajectory driven by increasing demand for its products and services. The company benefits from its global manufacturing footprint, comprehensive product portfolio, and strategic acquisitions. However, it faces challenges related to intense competition and regulatory requirements and its reliance on key customers. STVN has potential to increase its revenue, but must watch out for over dependence of a few clients.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It should not be considered financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Stevanato Group SpA
Exchange NYSE | Headquaters Piombino Dese, PD, Italy | ||
IPO Launch date 2021-07-16 | CEO & Executive Chairman Mr. Franco Stevanato | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 5521 | Website https://www.stevanatogroup.com |
Full time employees 5521 | Website https://www.stevanatogroup.com | ||
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide solutions for biopharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. It operates through two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. The company offers drug containment solutions comprising pre-fillable syringes, cartridges, vials, and ampoules; in-vitro diagnostic solutions; drug delivery systems, including pen injectors, auto-injectors, and wearable injectors; diagnostic laboratory consumables; analytical and regulatory support services; medical devices; pharmaceutical visual inspection machines; assembling and packaging machines; glass forming machines; and after-sales services, such as spare parts and maintenance services. It also provides contract development and manufacturing services for customer-owned drug delivery devices. The company serves pharmaceutical, biotechnology, diagnostics, and life sciences companies; and drug product, glass packaging, and fill and finish contract manufacturers. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.